SCHEMBL1340449

SCHEMBL1340449

Cn1nnnc1Sc1sc(NC(=O)Nc2ccc(Cl)cc2C(=O)C2CCCC2)nc1CC(=O)O

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.36
ALDH1A1 P00352 4/20 0.34
CASP1 P29466 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GAA P10253 3/20 0.34
NPC1 O15118 4/20 0.33
RAB9A P51151 4/20 0.33
APOBEC3A P31941 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LMNA P02545 2/20 0.33
TSHR P16473 2/20 0.33
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
GCK P35557 1/20 0.32
MCL1 Q07820 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1342757 0.92 LMNA (0.40) MAPTALDH1A1GAANPC1RAB9A
SCHEMBL1341982 0.91 LMNA (0.34) MAPTALDH1A1GAANPC1RAB9A
SCHEMBL1342032 0.90 ALDH1A1 (0.39) MAPTALDH1A1HSD17B10GAANPC1
SCHEMBL1341891 0.90 MAPT (0.42) MAPTALDH1A1NPC1RAB9ALMNA
SCHEMBL1342042 0.90 RAB9A (0.33) MAPTALDH1A1HSD17B10GAANPC1
SCHEMBL1343490 0.89 L3MBTL1 (0.36) MAPTALDH1A1CASP1HSD17B10GAA
SCHEMBL1341830 0.89 LMNA (0.36) MAPTALDH1A1NPC1RAB9ALMNA
SCHEMBL1343086 0.89 ALDH1A1 (0.35) MAPTALDH1A1CASP1HSD17B10GAA
SCHEMBL1342747 0.89 MAPT (0.36) MAPTALDH1A1CASP1HSD17B10GAA
SCHEMBL1342065 0.87 RAB9A (0.34) MAPTALDH1A1HSD17B10GAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 MAPT 2678/4885ALDH1A1 192/4885CASP1 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.